Factors Associated With Poor Outcomes in Adults With Newly Diagnosed Ulcerative Colitis

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 4, 2015, Pages 635-642

  Reinisch, Walter ^a   Reinink, Andrew R ^b   Higgins, Peter D R ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

IBD; Prognosis; TNF Inhibitor; Treatment; Tumor Necrosis Factor

Indexed keywords

BIOLOGICAL MARKER; HEMOGLOBIN; IMMUNOLOGIC FACTOR;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; COLONOSCOPY; COMORBIDITY; ENDOSCOPY; FACTORIAL ANALYSIS; FEMALE; GENETIC MARKER; HISTOPATHOLOGY; HUMAN; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PROGNOSTIC ASSESSMENT; RISK FACTOR; SEROLOGY; SMOKING; ULCERATIVE COLITIS; YOUNG ADULT; COLITIS, ULCERATIVE; EARLY DIAGNOSIS; PROGNOSIS; SECONDARY PREVENTION; TREATMENT OUTCOME;

COLITIS, ULCERATIVE; EARLY DIAGNOSIS; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; PROGNOSIS; SECONDARY PREVENTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84925147484     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2014.03.037     Document Type: Article

References (85)

1. Solberg I.C., Lygren I., Jahnsen J., et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol 2009, 44:431-440.
2. Andrews J.M. Le plus ca change: why we need better biomarkers to predict outcomes in ulcerative colitis. JGastroenterol Hepatol 2011, 26:1085-1086.
3. Ananthakrishnan A.N., McGinley E.L., Binion D.G., et al. Simple score to identify colectomy risk in ulcerative colitis hospitalizations. Inflamm Bowel Dis 2010, 16:1532-1540.
4. Höie O., Wolters F., Riis L., et al. Ulcerative colitis: patient characteristics may predict 10-yr disease recurrence in a European-wide population-based cohort. Am J Gastroenterol 2007, 102:1692-1701.
5. Targownik L.E., Singh H., Nugent Z., et al. The epidemiology of colectomy in ulcerative colitis: results from a population-based cohort. Am J Gastroenterol 2012, 107:1228-1235.
6. Kaplan G.G., Seow C.H., Ghosh S., et al. Decreasing colectomy rates for ulcerative colitis: a population-based time trend study. Am J Gastroenterol 2012, 107:1879-1887.
7. Ananthakrishnan A.N., Issa M., Beaulieu D.B., et al. History of medical hospitalization predicts future need for colectomy in patients with ulcerative. Inflamm Bowel Dis 2009, 15:176-181.
8. Bojic D., Radojicic Z., Nedeljkovic-Protic M., et al. Long-term outcome after admission for acute severe ulcerative colitis in Oxford: the 1992-1993 cohort. Inflamm Bowel Dis 2009, 15:823-828.
9. Moskovitz D.N., Van Assche G., Maenhout B., et al. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol 2006, 4:760-765.
10. Sandborn W.J., Rutgeerts P., Feagan B.G., et al. Colectomy comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009, 137:1250-1260.
11. Ferrante M., Vermeire S., Fidder H., et al. Long-term outcome after infliximab for refractory ulcerative colitis. JCrohns Colitis 2008, 2:219-225.
12. Oussalah A., Evesque L., Laharie D., et al. Multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization. Am J Gastroenterol 2010, 105:2617-2625.
13. Cvancarova M., Solberg C., Vatn M., et al. Risk matrix model for prediction of colectomy in a population based study of ulcerative colitis patients. The IBSEN Study. Gut 2010, 59(Suppl III):A36. on behalf of the IBSEN Study Group.
14. OCEBM Levels of Evidence Working Group. The Oxford levels ofevidence 2. Oxford Centre for Evidence-Based Medicine. Available at: Accessed December 10,2013. http://www.cebm.net/index.aspx?o=5653.
15. Bitton A., Peppercorn M.A., Antonioli D.A., et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 2001, 120:13-20.
16. Kiss L.S., Lakatos P.L. Natural history of ulcerative colitis: current knowledge. Curr Drug Targets 2011, 12:1390-1395.
17. Roth L.S., Chande N., Ponich T., et al. Predictors of disease severity in ulcerative colitis patients from Southwestern Ontario. World J Gastroenterol 2010, 16:232-236.
18. Etchevers M.J., Aceituno M., Garcia-Bosch O., et al. Risk factors and characteristics of extent progression in ulcerative colitis. Inflamm Bowel Dis 2009, 15:1320-1325.
19. Ha C.Y., Newberry R.D., Stone C.D., et al. Patients with late-adult-onset ulcerative colitis have better outcomes than those withearly onset disease. Clin Gastroenterol Hepatol 2010, 8:682-687.
20. Boyko E.J., Perera D.R., Koepsell T.D., et al. Effects of cigarette smoking on the clinical course of ulcerative colitis. Scand J Gastroenterol 1988, 23:1147-1152.
21. Beaugerie L., Massot N., Carbonnel F., et al. Impact of cessation of smoking on the course of ulcerative colitis. Am J Gastroenterol 2001, 96:2113-2116.
22. Mahid S.S., Minor K.S., Soto R.E., et al. Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clin Proc 2006, 81:1462-1471.
23. Aldhous M.C., Drummond H.E., Anderson N., et al. Smoking habit and load influence age at diagnosis and disease extent in ulcerative colitis. Am J Gastroenterol 2007, 102:589-597.
24. Kuriyama M., Kato J., Fujimoto T., et al. Risk factors and indications for colectomy in ulcerative colitis patients are different according to patient's clinical background. Dis Colon Rectum 2006, 49:1307-1315.
25. Vermeire S., Van Assche G., Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys?. Gut 2006, 55:426-431.
26. Haritunians T., Taylor K.D., Targan S.R., et al. Genetic predictors of medically refractory ulcerative colitis. Inflamm Bowel Dis 2010, 16:1830-1840.
27. Iliev I.D., Funari V.A., Taylor K.D., et al. Interactions between commensal fungi and the C-type lectin receptor Dectin-1 influence colitis. Science 2012, 336:1314-1317.
28. Gower-Rousseau C., Dauchet L., Vernier-Massouille G., et al. The natural history of pediatric ulcerative colitis: a population-based cohort study. Am J Gastroenterol 2009, 104:2080-2088.
29. Charpentier C., Salleron J., Savoye G., et al. Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. Gut 2014, 63:423-432.
30. Shiga H., Takagi S., Inoue R., et al. What determines the later clinical course of patients who do not undergo colectomy at the first attack? A Japanese cohort study on ulcerative colitis. Digestion 2010, 80:104-112.
31. Benazzato L., D'Incà R., Grigoletto F., et al. Prognosis of severe attacks in ulcerative colitis: effect of intensive medical treatment. Dig Liver Dis 2004, 36:461-466.
32. Seo M., Okada M., Yao T., et al. An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol 1992, 87:971-976.
33. Seo M., Okada M., Yao T., et al. Evaluation of the clinical course of acute attacks in patients with ulcerative colitis through the use of an activity index. JGastroenterol 2002, 37:29-34.
34. Truelove S.C., Witts L.J. Cortisone in ulcerative colitis. Final report on a therapeutic trial. BMJ 1955, 2:1041-1048.
35. Travis S.P., Farrant J., Ricketts C., et al. Predicting outcome in severe ulcerative colitis. Gut 1996, 38:905-910.
36. Lindgren S.C., Flood L.M., Kilander A.F., et al. Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol 1998, 10:831-835.
37. Ho G.T., Mowat C., Goddard C.J., et al. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Aliment Pharmacol Ther 2004, 19:1079-1087.
38. Kumar S., Ghoshal U.C., Aggarwal R., et al. Severe ulcerative colitis: prospective study of parameters determining outcome. JGastroenterol Hepatol 2004, 19:1247-1252.
39. Henriksen M., Jahnsen J., Lygren I., et al. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut 2008, 57:1518-1523.
40. Tibble J.A., Sigthorsson G., Bridger S., et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients withinflammatory bowel disease. Gastroenterology 2000, 119:15-22.
41. Costa F., Mumolo M.G., Ceccarelli L., et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut 2005, 54:364-368.
42. D'Incà R., Dal Pont E., Di Leo V., et al. Can calprotectin predict relapse risk in inflammatory bowel disease?. Am J Gastroenterol 2008, 103:2007-2014.
43. Ho G.T., Lee H.M., Brydon G., et al. Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis. Am J Gastroenterol 2009, 104:673-678.
44. García-Sánchez V., Iglesias-Flores E., González R., et al. Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis?. JCrohns Colitis 2010, 4:144-152.
45. Mendoza J.L., Abreu M.T. Biological markers in inflammatory bowel disease: practical consideration for clinicians. Gastroenterol Clin Biol 2009, 33(Suppl 3):S158-S173.
46. Mazlam M.Z., Hodgson H.J. Why measure C reactive protein?. Gut 1994, 35:5-7.
47. Burri E., Beglinger C. Faecal calprotectin-a useful tool in the management of inflammatory bowel disease. Swiss Med Wkly 2012, 142:w13557. Available at:, Accessed December 10, 2013. http://www.smw.ch/scripts/stream_pdf.php?doi=smw-2012-13557.
48. van Rheenen P.F. Role of fecal calprotectin testing to predict relapse in teenagers with inflammatory bowel disease who report full disease control. Inflamm Bowel Dis 2012, 18:2018-2025.
49. D'Haens G., Ferrante M., Vermeire S., et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 2012, 18:2218-2224.
50. Higgins PD, Waljee AK, Aldrich L, et al. University of Michigan severe ulcerative colitis protocol. Version 2.5, November 28, 2011. Available at: Accessed February 17,2013. http://www.med.umich.edu/ibd/docs/UMSevereUCProtocol.2.5.pdf.
51. Moore J.C., Thompson K., Lafleur B., et al. Clinical variables as prognostic tools in pediatric-onset ulcerative colitis: a retrospective cohort study. Inflamm Bowel Dis 2011, 17:15-21.
52. Lombardi G., Annese V., Piepoli A., et al. Antineutrophil cytoplasmic antibodies in inflammatory bowel disease: clinical roleand review of the literature. Dis Colon Rectum 2000, 43:999-1007.
53. Sandborn W.J., Landers C.J., Tremaine W.J., et al. Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study. Mayo Clin Proc 1996, 71:431-436.
54. Vermeire S., Van Assche G., Rutgeerts P. Role of genetics in prediction of disease course and response to therapy. World J Gastroenterol 2010, 16:2609-2615.
55. Carbonnel F., Lavergne A., Lémann M., et al. Colonoscopy of acute colitis. A safe and reliable tool for assessment of severity. Dig Dis Sci 1994, 39:1550-1557.
56. Rutgeerts P., Sandborn W.J., Feagan B., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. NEngl J Med 2005, 353:2462-2476.
57. Frøslie K.F., Jahnsen J., Moum B.A., et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007, 133:412-422.
58. Ardizzone S., Cassinotti A., Duca P., et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol 2011, 9:483-489.
59. Colombel J.F., Rutgeerts P., Reinisch W., et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011, 141:1194-1201.
60. Fujiya M., Saitoh Y., Nomura M., et al. Minute findings by magnifying colonoscopy are useful for the evaluation of ulcerative colitis. Gastrointest Endosc 2002, 56:535-542.
61. Nishio Y., Ando T., Maeda O., et al. Pit patterns in rectal mucosa assessed by magnifying colonoscope are predictive of relapse in patients with quiescent ulcerative colitis. Gut 2006, 55:1768-1773.
62. Watanabe C., Sumiokak M., Hiramoto T., et al. Magnifying colonoscopy used to predict disease relapse in patients with quiescent ulcerative colitis. Inflamm Bowel Dis 2009, 15:1663-1669.
63. Tanaka M., Saito H., Kusumi T., et al. Biopsy pathology predicts patients with ulcerative colitis subsequently requiring surgery. Scand J Gastroenterol 2002, 37:200-205.
64. Hefti M.M., Chessin D.B., Harpaz N., et al. Severity of inflammation as a predictor of colectomy in patients with chronic ulcerative colitis. Dis Colon Rectum 2009, 52:193-197.
65. Melson J.E., Giusto D., Kwasny M., et al. Histopathology predictors of medically refractory ulcerative colitis. Dis Colon Rectum 2010, 53:1280-1286.
66. Bessissow T., Lemmens B., Ferrante M., et al. Prognostic value of serologic and histologic markers on clinical relapse in ulcerative colitis patients with mucosal healing. Am J Gastroenterol 2012, 107:1684-1692.
67. Dinesen L.C., Walsh A.J., Protic M.N., et al. The pattern and outcome of acute severe colitis. JCrohns Colitis 2010, 4:431-437.
68. Molnár T., Farkas K., Nyári T., et al. Response to first intravenous steroid therapy determines the subsequent risk of colectomy in ulcerative colitis patients. JGastrointest Liver Dis 2011, 20:359-363.
69. Allez M., Lemann M. Role of endoscopy in predicting the disease course in inflammatory bowel disease. World J Gastroenterol 2010, 16:2626-2632.
70. Ando T., Nishio Y., Watanabe O., et al. Value of colonoscopy for prediction of prognosis in patients with ulcerative colitis. World J Gastroenterol 2008, 14:2133-2136.
71. Selby S. The natural history of ulcerative colitis. Baillieres Clin Gastroenterol 1997, 11:53-64.
72. Loftus E.V., Harewood G.C., Loftus C.G., et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005, 54:91-96.
73. Terg R., Sambuelli A., Coronel E., et al. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis and the risk of developing malignancies. A large prospective study. Acta Gastroenterol Latinoam 2008, 38:26-33.
74. Dave M., Elmunzer B.J., Dwamena B.A., et al. Primary sclerosing cholangitis: meta-analysis of diagnostic performance of MR cholangiopancreatography. Radiology 2010, 256:387-396.
75. Aragon G., Younossi Z.M. When and how to evaluate mildly elevated liver enzymes in apparently healthy patients. Cleve Clin J Med 2010, 77:195-204.
76. Rasmussen H.H., Fallingborg J., Mortensen P.B., et al. Primary sclerosing cholangitis in patients with ulcerative colitis. Scand J Gastroenterol 1992, 27:732-736.
77. Joo M., Abreu-e-Lima P., Farraye F., et al. Pathologic features of ulcerative colitis in patients with primary sclerosing cholangitis: a case-control study. Am J Surg Pathol 2009, 33:854-862.
78. Lundqvist K., Broomé U. Differences in colonic disease activity in patients with ulcerative colitis with and without primary sclerosing cholangitis: a case control study. Dis Colon Rectum 1997, 40:451-456.
79. Goodhand J.R., Alazawi W., Ramton D.S. Systematic review: Clostridium difficile and inflammatory bowel disease. Aliment Pharmacol Ther 2010, 33:428-441.
80. Navaneethan U., Venkatesh P.G., Shen B. Clostridium difficile infection and inflammatory bowel disease: understanding the evolving relationship. World J Gastroenterol 2010, 16:4892-4904.
81. Nguyen M., Bradford K., Zhang X., et al. Cytomegalovirus reactivation in ulcerative colitis patients. Ulcers 2011, 2011:1-7.
82. Travis S., Satsangi, Lemann M. Predicting the need for colectomy in severe ulcerative colitis: a critical appraisal of clinical parameters and currently available biomarkers. Gut 2011, 60:3-9.
83. Turner D., Mack D., Leleiko N., et al. Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response. Gastroenterology 2010, 138:2282-2291.
84. Sydora M.J., Sydora B.C., Fedorak R.N. Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome. JCrohns Colitis 2012, 6:207-214.
85. Van Assche G., Vermeire S., Rutgeerts P. Management of acute severe ulcerative colitis. Gut 2011, 60:130-133.